Journal
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume 9, Issue 12, Pages 457-465Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v9.i12.457
Keywords
Pancreatic adenocarcinoma; Neoadjuvant chemotherapy; Neoadjuvant chemoradiation therapy; Metaanalysis; Decision analysis; Borderline resectable; Locally advanced; Randomized controlled trial; Phase I trial; Phase II trial; Phase III trial
Categories
Ask authors/readers for more resources
The use of neoadjuvant therapies has played a major role for borderline resectable and locally advanced pancreatic cancers (PCs). For this group of patients, preoperative chemotherapy or chemoradiation has increased the likelihood of surgery with negative resection margins and overall survival. On the other hand, for patients with resectable PC, the main rationale for neoadjuvant therapy is that the overall survival with current strategies is unsatisfactory. There is a consensus that we need new treatments to improve the overall survival and quality of life of patients with PC. However, without strong scientific evidence supporting the theoretical advantages of neoadjuvant therapies, these potential benefits might turn out not to be worth the risk of tumors progression while waiting for surgery. The focus of this paper is to provide the readers an overview of the most recent evidence on this subject.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available